Fig. 4

PLCβ2 inhibits TAK1 activation. a IB of cell lysates from HEK293 cells expressing TAK1 and TAB1 in the presence or absence of PLCβ2. b, c Reporter assay of NF-κB (b) and AP-1 (c) activation in HEK293T cells expressing TAK1 and TAB1 with increasing concentrations of PLCβ2. d Immunoblot analysis of lysates from wild-type or Plcb2^−/− macrophages treated with poly(I:C) for the indicated times using phospho-TAK1 antibody. e IB of lysates from wild-type or Plcb2^−/− macrophages pretreated with TAK1 inhibitor, (5Z)-7-oxozeaenol, for 1 h, then stimulated with poly(I:C) for the indicated times using anti-phospho-antibodies. f, g IB of PLCβ2 and p-TAK1 in PBMC from HFMD patients. Both PLCβ2 and p-TAK1 levels were classified as low, medium, or high based on the intensities of each band; the percentages of patients classified in each category are depicted the histogram in (f) and the representative IB is shown in (g). **p < 0.01 and ***p < 0.001 by unpaired t-test (b, c). Data are representative of three experiments with at least three independent biological replicates (n = 3 cultures in d, e)